Compare · ABBV vs RNA
ABBV vs RNA
Side-by-side comparison of AbbVie Inc. (ABBV) and Atrium Therapeutics Inc. (RNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and RNA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $500.94B, about 3813.2x RNA ($131.4M).
- Over the past year, ABBV is up 25.8% and RNA is down 84.3% - ABBV leads by 110.1 points.
- ABBV has been more active in the news (19 items in the past 4 weeks vs 12 for RNA).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- Atrium Therapeutics Inc.
- Price
- $285.46+0.75%
- $7.68-1.60%
- Market cap
- $500.94B
- $131.4M
- 1M return
- +8.10%
- -19.49%
- 1Y return
- +25.84%
- -84.27%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 19
- 12
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Atrium Therapeutics Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.
Latest ABBV
- SEC Form 8-K filed by AbbVie Inc.
- AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
- New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
- AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
- SEC Form 8-K filed by AbbVie Inc.
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
- AbbVie to Host Third-Quarter 2026 Earnings Conference Call
- FDA Approval for JUVMO issued to ABBVIE INC
Latest RNA
- Amendment: SEC Form 8-K/A filed by Atrium Therapeutics Inc.
- SEC Form 8-K filed by Atrium Therapeutics Inc.
- Atrium Therapeutics Announces $50 Million Private Placement
- Chief Scientific Officer Younis Husam covered exercise/tax liability with 11,216 shares, decreasing direct ownership by 21% to 41,441 units (SEC Form 4) to cover taxes
- Chief Medical Officer Hughes Steven George covered exercise/tax liability with 21,459 shares, decreasing direct ownership by 29% to 51,638 units (SEC Form 4) to satisfy withholding tax
- Director Boyce Sarah covered exercise/tax liability with 126,418 shares, decreasing direct ownership by 48% to 138,668 units (SEC Form 4) (withholding obligation)
- Director Flanagan W. Michael covered exercise/tax liability with 22,812 shares, decreasing direct ownership by 42% to 31,974 units (SEC Form 4) to satisfy withholding tax
- Officer Kenney Stephanie covered exercise/tax liability with 2,375 shares, decreasing direct ownership by 7% to 33,085 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Winslow Brendan R. covered exercise/tax liability with 6,742 shares, decreasing direct ownership by 15% to 36,859 units (SEC Form 4) (for withholding tax)
- Officer Gallagher Kathleen P. covered exercise/tax liability with 11,632 shares, decreasing direct ownership by 9% to 119,729 units (SEC Form 4) (for tax liability)